| Name | Title | Contact Details |
|---|
Founded in 1924, Baptist Health has been bringing advanced medical technology, modern facilities, and many of the region`s most prominent physicians and medical professionals to the communities of our commonwealth for nearly a century. Headquartered in Louisville, the Baptist Health family of hospitals, care centers, physician offices and health facilities has experienced tremendous growth in recent years. Baptist Health Floyd in New Albany, Ind. (formerly known as Floyd Memorial Hospital and Health Services), is the newest member, joined on Oct. 1, 2016. In 2012, we welcomed Baptist Health Richmond (formerly Pattie A. Clay Regional Medical Center) and Baptist Health Madisonville (formerly Trover Health System) to the fold. Our other hospitals include Baptist Health Paducah, Baptist Health Louisville, Baptist Health La Grange, Baptist Health Lexington and Baptist Health Corbin. We also manage Hardin Memorial Health in Elizabethtown. Counting all nine hospitals, we have more than 2,700 licensed beds. Baptist Health`s 250+ outpatient facilities offer Urgent Care, Express Care, Occupational Medicine, Physical Therapy, Diagnostics and Home Care services. Our physician network of more than 3,000 employed and affiliated physicians continues to grow as we endeavor to improve access to healthcare and enhance the health of Kentucky as a whole.
Excellance Inc is a Madison, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cape Medical Supply is a Sandwich, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Age Wave is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.